Lazard (NYSE:LAZ) reported quarterly earnings of $1.28 per share which beat the analyst consensus estimate of $0.88 by 45.45 percent. This is a 91.04 percent increase over earnings of $0.67 per share from the same period last year.
Awakn’s First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics
Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode.